

News

Clinical Laboratory Test Update

Lacosamide, Oxcarbazepine Metabolite, Topiramate, Zonisamide by LCMS

Effective May 16, 2022, the University of Colorado Hospital Clinical Laboratory will begin Lacosamide, Oxcarbazepine Metabolite, Topiramate, and Zonisamide anti-epileptic drug (AED) testing by Liquid Chromatography Mass Spectrometry (LCMS).

Test name	Lacosamide	Oxcarbazepine Metabolite	Topiramate	Zonisamide
EAP	LAB3459	LAB4312	LAB498	LAB504
Collect	One 6 mL plain red top tube, no gel NOTE: Only one 6 mL tube is needed, even if multiple tests are ordered.			
Storage/Transport	Internal: Deliver to lab immediately.			
	Offsite: Allow 30 minutes for red top to clot before centrifuging. Centrifuge within 2 hours of collection. Place at least 0.5 mL serum in aliquot container and send to lab refrigerated/on ice (2-8 °C). NOTE: Only one aliquot is needed, even if multiple tests are ordered.			
Stability	Prior to centrifugation: Ambient, 2 hours. Serum aliquot: Ambient, 6 weeks, Refrigerated (2-8 °C), 6 weeks; Frozen (-20 °C): 6 weeks			
Method	Liquid Chromatography – Tandem Mass Spectrometry (LCMS)			
Performed	Monday, Wednesday, Friday			
Reported	1-2 days			
Reference Interval	Therapeutic range suggested, not well established: 1.0 – 10.0 µg/mL Toxic range: > 20.0 µg/mL	Therapeutic range: 10.0 – 35.0 µg/mL Toxic range: > 40 µg/mL	Therapeutic range: 5.0 – 20.0 µg/mL Toxic range: not well established	Therapeutic range: 10.0 – 40.0 µg/mL Toxic range: > 80 µg/mL
CPT	80235	80183	80201	80203

Please contact Geza Bodor, MD at 720-848-6032 if you have any questions, or visit our website at <https://www.testmenu.com/universityhospital> for additional information.

Issued: May 5, 2022